Mukherjee J J, de Castro J J, Kaltsas G, Afshar F, Grossman A B, Wass J A, Besser G M
Department of Endocrinology, St Bartholomew's Hospital, London, UK.
Clin Endocrinol (Oxf). 1997 Jul;47(1):51-60. doi: 10.1046/j.1365-2265.1997.2151035.x.
The insulin tolerance test (ITT) is the established reference test for assessing the hypothalamo-pituitary-adrenal (HPA) axis. Various authorities, however, have suggested that the 250 microgram short ACTH stimulation test may be used to assess the HPA axis in place of the ITT in suspected hypopituitarism, although a number of other studies have suggested that the test may be unreliable in this setting. In this study, the ITT (or glucagon test) has been compared with the 250 microgram short ACTH stimulation test in patients with pituitary tumours pre-operatively and within 2 weeks of trans-sphenoidal hypophysectomy.
An ITT, or a glucagon test when the ITT was contraindicated, and the 250 micrograms short ACTH stimulation test, were performed in all the patients before (an ITT in 18 and a glucagon test in three patients) and within 2 weeks after trans-sphenoidal hypophysectomy (an ITT in 16 and a glucagon test in five patients).
Twenty-one patients with pituitary disorders (15 with acromegaly, one with a prolactinoma and five with non-functioning tumours) were studied; four had a microadenoma, two a mesoadenoma and 15 a macroadenoma.
Serum cortisol was measured by radioimmunoassay. A normal response was defined as a rise in serum cortisol to 580 nmol/l or above for all the tests.
Before surgery, three of 18 patients (17%) had a discrepancy between the ITT and the 30 minute short ACTH stimulation test and one of three between the glucagon test and the 30 minute short ACTH stimulation test. Combined together, pre-operatively, four of 21 patients (19%) had discrepant results. In the early post-operative period, the discrepancy between ITT and the 30 minute short ACTH stimulation test was higher with four of 16 patients (25%) showing discordant results; one of the five patients tested had a discrepancy between the glucagon test and the 30 minute short ACTH stimulation test. On combining the tests, the post-operative discrepancy was five of 21 patients (24%).
The 250 microgram short ACTH stimulation test produces discordant results from the ITT in a clinically significant proportion of affected patients when assessing the HPA axis, although the rate of discordance varies according to the criteria used for normality for both the tests. We suggest that the ITT should remain the preferred test for assessing ACTH secretory capacity compared with the standard 250 microgram short ACTH stimulation test, both in the preoperative and in the early post-trans-sphenoidal hypophysectomy period.
胰岛素耐量试验(ITT)是评估下丘脑 - 垂体 - 肾上腺(HPA)轴的既定参考试验。然而, various authorities(此处“various authorities”应结合上下文准确翻译,可理解为“多个权威机构”)建议,在疑似垂体功能减退症中,250微克短促肾上腺皮质激素(ACTH)刺激试验可用于替代ITT来评估HPA轴,尽管其他一些研究表明该试验在这种情况下可能不可靠。在本研究中,对垂体肿瘤患者在术前及经蝶窦垂体切除术术后2周内,将ITT(或胰高血糖素试验)与250微克短ACTH刺激试验进行了比较。
对所有患者在经蝶窦垂体切除术之前(18例进行ITT,3例进行胰高血糖素试验)以及术后2周内(16例进行ITT,5例进行胰高血糖素试验)进行了ITT或在ITT禁忌时进行胰高血糖素试验,以及250微克短ACTH刺激试验。
研究了21例垂体疾病患者(15例肢端肥大症、1例催乳素瘤和5例无功能肿瘤患者);4例为微腺瘤,2例为中腺瘤,15例为大腺瘤。
采用放射免疫分析法测定血清皮质醇。所有试验中,正常反应定义为血清皮质醇升高至580 nmol/l或更高。
术前,18例患者中有3例(17%)的ITT与30分钟短ACTH刺激试验结果存在差异,3例胰高血糖素试验患者中有1例与30分钟短ACTH刺激试验结果存在差异。术前合并计算,21例患者中有4例(19%)结果不一致。术后早期,ITT与30分钟短ACTH刺激试验之间的差异更高,16例患者中有4例(25%)结果不一致;5例接受测试的患者中有1例胰高血糖素试验与30分钟短ACTH刺激试验结果存在差异。综合各项试验,术后不一致率为21例患者中有5例(24%)。
在评估HPA轴时,250微克短ACTH刺激试验在相当比例的受影响患者中产生与ITT不一致的结果,尽管不一致率根据两种试验的正常标准而有所不同。我们建议,与标准的250微克短ACTH刺激试验相比,无论是在术前还是经蝶窦垂体切除术后早期,ITT仍应是评估ACTH分泌能力的首选试验。